Chris Donaldson
Research Associate at Baxter Healthcare
Articles
Formulation Studies of an Adsorbed Conjugate Vaccine
October 2nd 2008NeisVac-C is a polysaccharide-protein conjugate vaccine for use against Neisseria meningitidis serogroup C infection. The Phase 1 clinical formulation consisted of physiological saline, thimerosal, and aluminum hydroxide. The long-term stability data for both the PBS and saline formulations are presented in this article.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 23rd 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 23rd 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 23rd 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 23rd 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
